NEW YORK (GenomeWeb News) – Med BioGene said today that it has expanded its lymphoma diagnostics collaboration with Duke University to include additional collaborators from Northwestern University, Indiana University, and the University of Hong Kong.
Vancouver, BC-based Med BioGene said the expansion of the collaboration was facilitated through Duke’s establishment of the Working Group in Hematologic Malignancies. The first project of the group is to develop genomic-based tests for lymphoma, including Med BioGene’s LymphExpress Dx.
Med BioGene and Duke formed their collaboration in March 2007 to develop and validate biomarkers for lymphoma and leukemia. Under that collaboration, Duke is providing samples for Med BioGene’s gene expression-profiling system.
Erinn Brishko, CEO of Med BioGene, said that the expanded alliance “provides a significant base of expertise in all required areas and patient samples for analysis.”